APA (7th ed.) Citation

M, M., AL, R. S., S, J., DK, V., JD, J., H, X., . . . S, V. (2025). The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. Molecular cancer therapeutics, 24(9), 1308. https://doi.org/10.1158/1535-7163.MCT-25-0130

Chicago Style (17th ed.) Citation

M, Mahajan, et al. "The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer." Molecular Cancer Therapeutics 24, no. 9 (2025): 1308. https://doi.org/10.1158/1535-7163.MCT-25-0130.

MLA (9th ed.) Citation

M, Mahajan, et al. "The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer." Molecular Cancer Therapeutics, vol. 24, no. 9, 2025, p. 1308, https://doi.org/10.1158/1535-7163.MCT-25-0130.